INM
Price
$4.95
Change
+$0.45 (+10.00%)
Updated
Jan 17 closing price
Capitalization
3.58M
SPHRY
Price
$0.80
Change
+$0.05 (+6.67%)
Updated
Jan 17 closing price
Capitalization
31.16M
45 days until earnings call
Ad is loading...

INM vs SPHRY

Header iconINM vs SPHRY Comparison
Open Charts INM vs SPHRYBanner chart's image
InMed Pharmaceuticals
Price$4.95
Change+$0.45 (+10.00%)
Volume$39.84K
Capitalization3.58M
Starpharma Holdings
Price$0.80
Change+$0.05 (+6.67%)
Volume$1.5K
Capitalization31.16M
INM vs SPHRY Comparison Chart
Loading...
INM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INM vs. SPHRY commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INM is a Hold and SPHRY is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (INM: $4.95 vs. SPHRY: $0.80)
Brand notoriety: INM and SPHRY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INM: 122% vs. SPHRY: 21%
Market capitalization -- INM: $3.58M vs. SPHRY: $31.16M
INM [@Biotechnology] is valued at $3.58M. SPHRY’s [@Biotechnology] market capitalization is $31.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INM’s FA Score shows that 0 FA rating(s) are green whileSPHRY’s FA Score has 1 green FA rating(s).

  • INM’s FA Score: 0 green, 5 red.
  • SPHRY’s FA Score: 1 green, 4 red.
According to our system of comparison, SPHRY is a better buy in the long-term than INM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INM’s TA Score shows that 2 TA indicator(s) are bullish while SPHRY’s TA Score has 5 bullish TA indicator(s).

  • INM’s TA Score: 2 bullish, 5 bearish.
  • SPHRY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SPHRY is a better buy in the short-term than INM.

Price Growth

INM (@Biotechnology) experienced а +14.85% price change this week, while SPHRY (@Biotechnology) price change was +21.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

INM is expected to report earnings on Nov 14, 2024.

SPHRY is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPHRY($31.2M) has a higher market cap than INM($3.59M). SPHRY YTD gains are higher at: 24.359 vs. INM (7.843).
INMSPHRYINM / SPHRY
Capitalization3.59M31.2M11%
EBITDA-6.66MN/A-
Gain YTD7.84324.35932%
P/E Ratio0.02N/A-
Revenue4.96MN/A-
Total Cash5.58MN/A-
Total Debt1.06MN/A-
FUNDAMENTALS RATINGS
INM vs SPHRY: Fundamental Ratings
INM
SPHRY
OUTLOOK RATING
1..100
6184
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
8342
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPHRY's Valuation (32) in the null industry is in the same range as INM (43). This means that SPHRY’s stock grew similarly to INM’s over the last 12 months.

SPHRY's Profit vs Risk Rating (100) in the null industry is in the same range as INM (100). This means that SPHRY’s stock grew similarly to INM’s over the last 12 months.

SPHRY's SMR Rating (96) in the null industry is in the same range as INM (98). This means that SPHRY’s stock grew similarly to INM’s over the last 12 months.

SPHRY's Price Growth Rating (42) in the null industry is somewhat better than the same rating for INM (83). This means that SPHRY’s stock grew somewhat faster than INM’s over the last 12 months.

SPHRY's P/E Growth Rating (100) in the null industry is in the same range as INM (100). This means that SPHRY’s stock grew similarly to INM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMSPHRY
RSI
ODDS (%)
N/A
Bullish Trend 11 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
85%
Momentum
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
66%
MACD
ODDS (%)
Bullish Trend 11 days ago
90%
Bullish Trend 11 days ago
62%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
63%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
58%
Advances
ODDS (%)
Bullish Trend 16 days ago
86%
Bullish Trend 24 days ago
63%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend about 1 month ago
76%
BollingerBands
ODDS (%)
N/A
Bearish Trend 11 days ago
86%
Aroon
ODDS (%)
N/A
Bearish Trend 11 days ago
85%
View a ticker or compare two or three
Ad is loading...
INM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NVVE2.970.20
+7.22%
Nuvve Holding Corp
KRMD4.090.09
+2.25%
KORU Medical Systems
WPP45.110.48
+1.08%
WPP PLC
HEES88.12-0.63
-0.71%
H&E Equipment Services
CDNA21.44-0.62
-2.81%
CareDx

INM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INM has been loosely correlated with TFFP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INM jumps, then TFFP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INM
1D Price
Change %
INM100%
+10.00%
TFFP - INM
53%
Loosely correlated
N/A
TTNP - INM
48%
Loosely correlated
+21.94%
EYEN - INM
39%
Loosely correlated
-5.15%
OMER - INM
36%
Loosely correlated
+1.63%
VTYX - INM
31%
Poorly correlated
+6.88%
More

SPHRY and

Correlation & Price change

A.I.dvisor tells us that SPHRY and VACBF have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SPHRY and VACBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHRY
1D Price
Change %
SPHRY100%
+5.96%
VACBF - SPHRY
29%
Poorly correlated
N/A
TTNP - SPHRY
27%
Poorly correlated
+21.94%
SPHRF - SPHRY
25%
Poorly correlated
N/A
ASPHF - SPHRY
22%
Poorly correlated
N/A
INM - SPHRY
21%
Poorly correlated
+10.00%
More